Comparative Pharmacology
Head-to-head clinical analysis: CAVERJECT IMPULSE versus CERVIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAVERJECT IMPULSE versus CERVIDIL.
CAVERJECT IMPULSE vs CERVIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 that causes vasodilation and relaxation of trabecular smooth muscle in the corpus cavernosum, leading to increased blood flow and penile erection.
Prostaglandin E2 (PGE2) receptor agonist; induces cervical ripening and uterine contractions via binding to EP receptors, increasing intracellular calcium and promoting gap junction formation.
2.5 to 60 mcg intracavernosal injection as needed for erection, maximum 3 times per week with at least 24 hours between doses. Initial dose: 2.5 mcg, titrate based on response.
10 mg vaginal insert (dinoprostone) placed high in the posterior vaginal fornix; may be removed after 12 hours or onset of active labor; one insert per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2.5 minutes following intravenous administration, due to rapid pulmonary metabolism; after intracavernosal injection, local half-life is extended to about 30-60 minutes due to depot effect.
Terminal elimination half-life of dinoprostone is 2.5 to 5 minutes; clinical effects persist due to sustained release formulation (e.g., vaginal insert).
Primarily metabolized in the lung by enzymatic hydrolysis; urinary excretion accounts for approximately 70-90% of the administered dose as metabolites, with less than 3% excreted unchanged in urine; fecal excretion is minimal (<1%).
Primarily hepatic metabolism via 15-hydroxyprostaglandin dehydrogenase; metabolites are excreted renally (approximately 60% over 24 hours) and fecally (approximately 40%).
Category C
Category C
Prostaglandin
Prostaglandin